Welcome to our dedicated page for YULONG ECO MATERIALS news (Ticker: YECO), a resource for investors and traders seeking the latest updates and insights on YULONG ECO MATERIALS stock.
YULONG ECO MATERIALS LTD, now known as EV Biologics Corp, is a biotechnology company based in Wyoming, USA. Their focus lies in developing stem cell-derived exosome-based therapeutic products and biocompatible formulations to enhance bioactivity and potency. Through advanced biomanufacturing, bioengineering, and bioinformatics, they aim to optimize nanoparticle-based biologics for various clinical applications, including regenerative medicine and longevity.
EV Biologics also owns Excyte, a subsidiary focused on developing biotherapeutics from living cells. Their innovative approach utilizes nanotherapeutic platforms to deliver bioactive molecules to target cells, combat aging, and promote longevity. With a strong emphasis on research and development, as well as collaboration with commercial partners, EV Biologics is poised to revolutionize modern medicine with their groundbreaking therapeutic solutions.
EV Biologics Corp (OTC PINK:YECO) announced the successful generation of several mesenchymal stem/stromal cell (MSC) lines for secretome production. The isolated cell banks were obtained from rigorously screened human donor tissue and confirmed their identity as MSCs. These cell lines will be utilized for the production of secretome products, including extracellular vesicles and other bioactive proteins. The company emphasizes the therapeutic potential of MSC secretome, particularly from young stem cells. CEO Daniel Mckinney stated that the creation of the cell bank has been a priority since 2020, laying the foundation for future therapeutic development initiatives.
EV Biologics Corp. (OTC PINK: YECO) has successfully closed a funding round raising $1,000,000 of its $2.5 million initial capitalization goal. A total of 100,000 shares were issued at $10 each from a planned 10 million shares issuance. The funding aims to enhance stem cell bank operations and advance secretome product development. Excyte, a subsidiary, is focused on revolutionizing regenerative therapeutics. The company plans to finalize the remaining capital raise by the end of Q1 2023.
EV Biologics Corp (OTC PINK:YECO) is initiating a PCAOB audit for 2021 and 2022, aiming to apply for listing on the OTCQX market in Q1 2023. The audit is essential for finalizing a corporate name change and updating the trading symbol. CEO Daniel McKinney announced advancements in their MSC secretome product development. Additionally, the subsidiary Excyte is expected to finalize its initial funding by year-end to enhance biomanufacturing technologies.
Currently, YECO has 7.22 million shares outstanding.
EV Biologics Corp (OTC Pink: YECO) has launched Excyte, Inc., a wholly owned subsidiary valued at $100 million. The subsidiary has raised $500,000 toward its $2.5 million initial capitalization goal. These funds will support biomanufacturing and the development of nanotherapeutics. Excyte aims to innovate in biomanufacturing and bioengineering, enhancing the therapeutic potential of stem cell-derived nanoparticles. With a focus on longevity, Excyte joins a niche market sector targeting regenerative medicine.
EV Biologics Corp (OTC PINK: YECO) announced a Manufacturing Services Agreement with Lonza to enhance its development of stem/progenitor cell-derived nanotherapeutics. This collaboration aims to expedite the biomanufacturing process and producer-cell line development by utilizing Lonza's established infrastructure in cell and gene therapy.
CEO Daniel Mckinney highlighted that this partnership allows EV Biologics to improve efficiency without significant investment in its own facilities, aiming for high-quality therapeutic products for various clinical conditions.
FAQ
What is the market cap of YULONG ECO MATERIALS (YECO)?
What is YULONG ECO MATERIALS LTD known for?
What is EV Biologics Corp's focus areas?
What subsidiary does EV Biologics Corp own?
How does EV Biologics Corp plan to revolutionize modern medicine?
What sets EV Biologics Corp apart in the biotechnology industry?
What clinical applications does EV Biologics Corp target?
Where is EV Biologics Corp based?
What recent achievements has EV Biologics Corp celebrated?
What future goals does EV Biologics Corp aim to achieve?
How does EV Biologics Corp approach research and development?
